# US 2025/0121133 A1 · Insulin infusion set

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0121133 A1
- Document ID: US20250121133A1
- Status: Published application
- Kind: A1
- Application number: 19/000,073
- Filed: 2024-12-23
- Published: 2025-04-17
- Earliest claimed: 2020-08-28
- Applicants: Tandem Diabetes Care, INC
- Inventors: Keith A. Oberg; Mark C. Estes; Kenneth C. Hsu; David S. Gillett
- Web page: https://patentgrep.com/patent/US20250121133A1

## CPC

- A61M 5/158: Needles {for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body}
- A61M 5/165: Filtering accessories, e.g. blood filters, filters for infusion liquids (A61M1/34, A61M5/36 take precedence)
- A61M 5/14244: {adapted to be carried by the patient, e.g. portable on the body}
- A61M 5/14248: {of the skin patch type}
- A61M 2005/14252: {with needle insertion means}
- A61M 2005/1585: {Needle inserters}
- A61M 2005/1587: {suitable for being connected to an infusion line after insertion into a patient}
- A61M 2205/0238: the material being a coating or protective layer
- A61M 2205/759: for removing preservatives, e.g. heavy metal compositions
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

Embodiments of devices and methods to maintain preservative concentration in a medication delivered using a medical device are provided. A barrier layer can be used to prevent migration of preservatives. A vent can be used to allow release of preservatives prior to delivery to the patient. An absorbent element can be used to maintain preservative concentration at a desired level. A filter can be used to capture particulates from the medication prior to delivery to a patient.

## Claims

### Claim 1

An insulin delivery system comprising:
a reservoir configured to hold an insulin medication therein;
an infusion hub;
tubing fluidically connecting the insulin reservoir and the infusion hub;
a cannula configured to deliver the insulin medication to a patient; and
an absorbent element positioned within the delivery system and in fluidic contact with the insulin medication, the absorbent element configured to absorb and store preservatives from the insulin medication.

### Claim 2 (depends on 1)

The insulin delivery system of claim 1, further comprising an impermeable backing layer adjacent to the absorbent element and configured to maintain the preservatives within the absorbent.

### Claim 3 (depends on 1)

The insulin delivery system of claim 1, wherein the absorbent element comprises EVOH, silicone, a low-density polymer, a PEG block-copolymer (e.g., PETG), PET, nylon, a nylon block-copolymer, a polymeric foam, or a polymeric monolith.

### Claim 4 (depends on 1)

The insulin delivery system of claim 1, wherein the absorbent element comprises a preservative capacity greater than a maximum concentration of preservative in the insulin medication.

### Claim 5 (depends on 1)

The insulin delivery system of claim 1, wherein the absorbent element is further configured to release preservatives to the insulin medication after storing the preservatives.

### Claim 6 (depends on 1)

The insulin delivery system of claim 1, wherein the absorbent element is configured to maintain the preservative concentration at a point of delivery to the patient at a concentration that minimizes local toxicity while maintaining insulin in a stable hexameric state.

### Claim 7 (depends on 6)

The insulin delivery system of claim 6, wherein the absorbent element is configured to maintain the preservative concentration at a concentration of greater than about 1.25 mg/mL.

### Claim 8 (depends on 6)

The insulin delivery system of claim 6, wherein the absorbent element is configured to maintain the preservative concentration at a concentration of about 1.15-1.75 mg/mL.

### Claim 9 (depends on 6)

The insulin delivery system of claim 6, wherein the absorbent element is configured to maintain the preservative concentration at a concentration of about 1.25-1.50 mg/mL.

### Claim 10 (depends on 1)

The insulin delivery system of claim 1, wherein the absorbent element comprises an interior layer of the tubing.

### Claim 11 (depends on 1)

The insulin delivery system of claim 1, wherein at least a portion of the insulin delivery system includes a barrier layer configured to prevent migration of preservatives from the insulin medication.

### Claim 12 (depends on 11)

The insulin delivery system of claim 11, wherein the tubing is a multi-layer tubing, and wherein the barrier layer is at least a portion of a layer of the multi-layer tubing.

### Claim 13 (depends on 11)

The insulin delivery system of claim 11, wherein the tubing is a multi-layer tubing, and wherein the barrier layer forms an entire layer of the multi-layer tubing.

### Claim 14 (depends on 11)

The insulin delivery system of claim 11, wherein the tubing comprises the barrier layer.

### Claim 15 (depends on 11)

The insulin delivery system of claim 11, wherein the barrier layer comprises a coating on the tubing.

### Claim 16 (depends on 11)

The insulin delivery system of claim 11, wherein the barrier layer comprises an inner layer of the tubing.

### Claim 17 (depends on 11)

The insulin delivery system of claim 11, wherein the barrier layer comprises polyether block-amide, HDPE, polypropylene, PTFE, chloro- and fluorosilicones, hydrochloro-, hydrofluoro-, and perfluoro-polymers, chlorinated polymers (e.g. viton), metal-coated polymers (e.g., mylar), poly carbonate, organic or inorganic plasma-deposited coatings (e.g. PTFE, PVC, halogenated siloxanes, silicon suboxides), vapor-deposited coatings (such as nitrides, titanium nitride, fluorocarbons, metals), Kapton, or parylene.

### Claim 18 (depends on 11)

The insulin delivery system of claim 11, further comprising a barrel connected to the cannula, and wherein the barrier layer is positioned on at least a portion of the barrel.

### Claim 19 (depends on 11)

The insulin delivery system of claim 11, comprising a connector comprising the barrier layer.

### Claim 20 (depends on 11)

The insulin delivery system of claim 11, wherein the barrier layer extends through an entire fluid path of the system.
